Vaccine targeting skin cancer shows promising results

Amen Clinics Associate Medical Director Dr. Eboni Cornish joins 'Fox & Friends First' to discuss a groundbreaking new mRNA melanoma vaccine from Merck and Moderna that reduced the risk of recurrence or death by 49% after five years.

A groundbreaking clinical trial reveals a new mRNA melanoma vaccine developed by Merck and Moderna reduces recurrence or death rates by 49 percent over five years. Dr. Eboni Cornish, Associate Medical Director of Amen Clinics, explains how this personalized immunotherapy uses artificial intelligence to target specific tumor mutations. This medical breakthrough represents the future of cancer treatment.